IMPORTANCE Cutaneous squamous cell carcinoma (cSCC) has metastatic potential, but the prognostic value of current staging systems in nonselected patients is uncertain.
C utaneous squamous cell carcinoma (cSCC) is increasing in incidence and is now ranked as the second most common skin cancer world-wide. 1 When excised surgically with free margins, the prognosis is mostly good, 2 but it is poor if metastasis has occurred. [3] [4] [5] Several staging systems for cSCC have been developed to predict patients' risk of metastasis and to individualize treatment and the follow-up schedule ( Figure 1 ). [6] [7] [8] [9] In 2011, the American Joint Committee on Cancer (AJCC) published the 7th edition of its staging system (AJCC 7), 6 which is based on tumor diameter and several risk features, including tumor depth, perineural invasion, primary site, and degree of differentiation as well as bone invasion. Although widely used, the AJCC 7 staging system has been criticized for low specificity and for being too complicated for use in clinical practice. 10 Other staging systems have been introduced by Breuninger and coworkers (hereinafter, Breuninger system), 8 primarily based on clinical tumor size and histological tumor thickness, and by a research group at the Brigham and Women's Hospital (BHW), 9 with 4 risk features defining the risk categories. Recently, an 8th edition of the AJCC staging system, to be used for cSCCs in the head-and-neck area only, has been introduced and will be implemented in 2018. 7 These 4 staging systems for cSCC have been constructed using patients from large, tertiary referral centers, and none of them has been validated using population-based patient cohorts, making their validity in nonselected patients uncertain. In this study, we aimed to externally validate the 4 staging systems using population-based data from a high-quality national cancer registry. The results are reported according to the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) statement.
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Methods
Since 1952, the Cancer Registry of Norway (CRN) has received compulsory information on all patients with cancer in Norway (population in 2015: approximately 5.2 million inhabitants). Information from several sources (eg, clinical records, pathology reports, and death certificates) ensures complete and high-quality data. 12 We defined cSCC according to the Inter- Within 5 years of individual follow-up, 112 patients were diagnosed as having metastasis (eFigure and eReferences in Supplement). Among the 6609 patients without metastasis during follow-up, 112 patients, matched for sex and age at diagnosis, were selected at random. Tissue blocks from excision specimens of the tumors from these 224 patients were retrieved from 20 hospital laboratories throughout Norway. Histological slides from the original tissue blocks were cut, stained with hematoxylin-eosin, and reexamined by an experienced pathologist (O.P.F.C.), who was blinded regarding the metastatic status of the patient, using well-established diagnostic criteria for cSCC. 13 When the diagnosis of cSCC could not be confirmed, the patient was excluded from further analyses, yielding a study sample of 103 patients with cSCC with metastasis (cases) and 81 patients without metastasis (controls goodness-of-fit, which reflects the agreement between observed outcomes and predictions. The calibration plot presents predicted probabilities (for groups) on the x-axis and the mean observed outcome on the y-axis. Perfect calibration should lie on a 45°line of the plot (ie, slope equals 1). The Hosmer-Lemeshow goodness-of-fit test is calculated when the number of "risk groups" is so large that continuous approximation is feasible. P < .05 indicates a poor calibration of the model. The plot and the Hosmer-Lemeshow test was calculated for the Breuninger system. The AJCC 7, AJCC 8, and BWH systems consisted of only 1 variable (eg, T-stages). Thus, the underlying assumption performing the Hosmer-Lemeshow test is not fulfilled, and a presentation of calibration plot is not justifiable. Furthermore, as a measure of overall performance, we considered the explained variation (R 2 ) by the model using the definition proposed by Nagelkerke.
14 Discrimination refers to the ability of a prediction model to differentiate between 2 outcome classes (ie, patients who developed metastasis and those who did not). Sensitivity, specificity, and proportion of cases correctly classified were used to evaluate classification performance. The concordance index (C-index), which is mathematically identical to area under the curve (AUC) for binary outcomes, is the most widely used measure to indicate discriminatory ability. The C-index can be interpreted as the probability that a patient with an outcome is given higher probability of the outcome by the model than a randomly chosen patient without the outcome. A value of 0.5 indicates that the model has no discriminatory ability, and a value of 1.0 indicates that the model has perfect discrimination ability. All data were analyzed using Stata statistical software (release 14; StataCorp LP).
Results
Mean age at diagnosis of cSCC was lower in patients with metastasis, particularly in those using immunosuppressive medication ( Table 1 ). In patients with metastasis, primary tumor was more frequently located on ear and lip, had more often a diameter greater than 2 cm, tumor thickness greater than 6 mm, invasion beyond subcutaneous fat, and poor differentiation, and was more often of desmoplastic type, compared with tumors in patients without metastasis (Table 1) . With 112 patients with cSCC developing metastasis within 5 years, the 5-year metastasis rate was 1.5%.
Staging
A large proportion of patients with (83 [85.6%]) and without (54 [66.7%]) metastasis fell into the T2 category of the AJCC 7 system, while none were in the T3 and T4 categories ( Table 2) . Using the Breuninger system, a higher proportion of patients with metastasis fell into the high-risk categories: tumor diameter, tumor thickness, and a combined variable of these and 1 or more of 4 high-risk features, compared with patients without metastasis ( Table 2) . Using the BWH system, most patients without metastasis fell into the T1 category, while patients with metastasis were almost equally distributed in the T1, T2a, and T2b categories (Table 2) . When the patients were categorized according to the AJCC 8 system, about 10% of the patients with and without metastasis fell into the T2 category, while less than 20% of patients without metastasis and more than 50% of patients with metastasis fell into the T3 category (Table 2) . No patients had tumors that fitted with the T4 category.
Risk of Metastasis
Using the AJCC 7 system, the risk of metastasis for T2 patients was 3-fold, compared with T1 patients (OR, 2.96; 95% CI, 1.43-6.15). Using the Breuninger system, the risk of metastasis were 6-fold for tumor diameter greater than 2 cm (OR, 5.92; 95% CI, 2.18-16.07), 9-fold for tumors with depth of invasion greater than 6 mm (OR, 9.00; 95% CI, 3.51-32.31), but less than 3-fold for tumors in the high-risk category of the combined variable (OR, 2.72; 95% CI, 1.29-5.74). The BWH system gave ORs for metastasis at 4.6 (95% CI, 2.23-9.49) and 21.31 
T Stage Risk Factors
T1
Tumor b High-risk factors: Tumor diameter Ն2 cm, invasion beyond subcutaneous fat, poorly differentiated, and perineural invasion.
Research Original Investigation
Finally, the AJCC 8 system gave 2-fold (OR, 2.00; 95% CI, 0.62-6.44) and 6-fold (OR, 6.14; 95% CI, 0.41-1.09) risk of metastasis for the T2 and T3 categories, respectively, although this was not statistically different from the T1 category. Invasion beyond subcutaneous fat was the strongest predictor for metastasis when using AJCC 8.
External Validation
The AJCC 7 system had highest sensitivity, but lowest specificity, lowest proportion of correctly classified cases, and results regarding C-index and R 2 test (Table 3 ). In contrast, AJCC 8 had lower sensitivity but much higher specificity and improvement in proportion of correctly classified tumors, C-index, and R 2 compared with AJCC 7. The BWH system had the highest specificity and the second highest proportion of correctly classified tumors and C-index. The external validation demonstrated the best results for the Breuninger system, with high sensitivity (77.3%), specificity (75.0%), correctly classified tumors (76.2%), and C-index (0.81). The model was well calibrated, with a slope of 0.97 and Hosmer-Lemeshow test P = .11, the largest value of R 2 (0.23) ( Figure 2 and Table 3 ).
Discussion
The goal of any cancer staging system is to separate patients with cancer into groups that have significantly different prognosis and different need for treatment and follow-up. These groups should differ in terms of outcome (distinctiveness), have similar outcome within each group (homogeneity), and have worsening outcome with increasing stage (monotonousness). By estimating the relative contribution of risk factors for metastasis from cSCC in multivariate data analyses, we have estimated the validity and usefulness of 4 staging systems in nonselected patients with cSCC. To our knowledge, this is the first study to externally validate current staging systems for cSCC using population-based data. The 4 staging systems distinguished poorly to moderately between patients who developed metastases and those who did not. The poorest results were found for the AJCC 7 system, which is most widely used. This is in line with results from hospital-based cohort studies. 3, 8, 9 The Breuninger system's high-risk categories and the BWH system's T2b category collected relatively homogenous groups. The BWH system and, to a lesser degree, the Breuninger system gave significantly elevated risk of metastasis by increasing stage or risk category. Although the AJCC 7 system gave increased risk of metastasis for T2 patients compared with T1 patients, no patients were in the T3 and T4 categories. Similar findings have been reported in hospital-based cohort studies, 8, 9 ,15 making this staging system less useful. Similar objections have been put forward by other authors based on clinical experience.
10,16-19
The AJCC 7 system has also been criticized for being too complicated owing to the high number of combined variables.
10,18,20
The Breuninger system is simpler, 8 being based on clinical tumor size (with 2 categories) and histological tumor thickness (with 3 categories). The BWH staging system is also relatively straightforward, with only 4 variables, with the number of prognostic factors defining the risk categories. 21 The AJCC 8 staging system is a major revision of the AJCC 7 system, including head and neck cSCCs only, and thereby limiting its usefulness.
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Only 1.5% of the cSCCs metastasized within 5 years, which is a considerably lower rate than the metastatic rate found in studies from tertiary centers. 4, [22] [23] [24] [25] [26] Our cohort is population-based, which we believe is a major strength, and probably includes more patients with small or thin cSCC than hospital-based studies. A recently published population-based study, from the United Kingdom, reports a cSCC metastasis rate of 1.2% (ie, close to our finding). 27 Our data were retrieved from a high-quality national cancer registry, yielding reliable data from nonselected patients. The CRN has been shown to be close to complete, 12 and there are no indications that this is not valid for cSCC metastasis too. Nevertheless, we cannot rule out that metastasis in some patients with cSCC may have been missed, especially in very old patients. By obtaining specimens from surgical excisions of primary cSCC in patients with and without metastasis, we were able to include all risk factors in the 4 staging systems. All specimens were reexamined by 1 experienced pathologist (O.P.F.C.), using well-established diagnostic criteria.
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Limitations A limitation of our study is that more controls than cases were excluded from the analyses after diagnostic reevaluation. However, the underlying assumption for performing the HosmerLemeshow test for the AJCC 7, BWH, and AJCC 8 systems would still not be fulfilled with more controls. Moreover, most ORs in our logistic regression analyses were significant, making it unlikely that an increase in the number of controls would change the results in a meaningful way. An additional search for more patients without metastasis would have been ideal, but was not possible within limited time and resources. Other Calibration plot of observed proportion against predicted probability of having metastasis in patients with cutaneous squamous cell carcinoma, based on risk features in the Breuninger et al 8 staging system. The dotted diagonal lines represent the ideal line where the actual probability of metastasis matches the predicted probability. The larger circles indicate that these points are based on more data. 
